Interestingly, it was sufficient to generate 2% of transduced cells (that correspond to 0.15% of CD45+ and MHC-II+ cells) to induce tumor growth delay and regression, providing a major advantage over other intratumoral immunotherapies such as oncolytic viruses, suicide gene approaches, and expression of co-stimulatory molecules or cytokines, which require high tumor cell transduction. The gene discussed is PTPRC; the disease is neoplasm.